Our oncology department consists of a team specialised in the diagnosis, treatment and follow-up of cancer. Our multidisciplinary approach in the fight against cancer allows us to offer personalised treatment plans to each of our patients.
As ONCO Assist in DEPTH, we aim to play a leading role in the fight against cancer and improve the quality of life of our patients by using the latest technology and research in our oncology department.
ONCOLOGY
HEMATOLOGY
In our haematology department, we have a team specialised in the diagnosis and treatment of blood and related tissue diseases. We use the latest technology and methods for the early diagnosis and effective treatment of various haematological diseases such as blood cancers, leukaemia, lymphoma and clotting disorders.
As ONCO Assist in DEPTH, we aim to provide the best care to our patients with the experience and knowledge of our specialists in our haematology department.
‘Cancer is a preventable and manageable disease with early diagnosis’
Cancer is a disease that develops mostly as a result of genetic mutations that accumulate over a lifetime; however, a certain proportion is associated with hereditary predispositions. In individuals with a family history of cancer, the risk of having a predisposition to this disease cannot be ignored. It is possible to assess this risk by examining cancer-related genes identified in scientific studies. Using the latest technology and scientific research, our expert team assesses the risk of cancer based on the genetic profile of the individual and allows you to take early measures. Today, familial cancer screening can be performed with only one tube of blood thanks to new generation sequencing technologies.
Somatic Tumour Panel
Pathological and genetic analyses on samples obtained from cancerous tissue are critical to determine the use of targeted therapies, immunotherapy and smart drugs and to direct patients to clinical trials. The success of new and effective drugs is often associated with concurrent chemotherapy and radiotherapy. Genetic profiling can show which treatment options are appropriate for patients, as well as which treatments should be avoided.
Liquid Biopsy
Some tumours may not be suitable for conventional biopsy due to their location or structure. This may make tumour profiling difficult. However, the genetic material released into circulation by cancer cells can be detected and analysed by liquid biopsy, a non-invasive method. Liquid biopsy is an important tool not only for monitoring the treatment process but also for assessing the risk of disease recurrence. The possibility of relapse can be screened with this method and preventive measures can be taken before relapse occurs.
Biomarker Tests
Biomarker tests provide important information to shape the patient's treatment plan by analysing specific genes or chromosomal changes. Unlike panels, biomarker tests are more rapid, targeted and drug-oriented analyses.
